ERBB2 and breast cancer: However, the majority of the studies assessing HER2 in node-positive BC have consistently shown HER2 overexpression to be associated with a worse prognosis, a finding consistent with the relatively high frequency of distant relapse (64%) in the HER2-enriched subgroup with locoregional nodal spread described in this study, compared with HER2 node-negative tumors (25%) [26–27].